EUVIMEDEUVIMED entdecken
Multizentrische Studie

Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

Tomomitsu Matono iD, Toshifumi Tada iD, Atsushi Hiraoka iD, Masashi Hirooka iD, Kazuya Kariyama iD, Joji Tani iD, Masanori Atsukawa iD, Koichi Takaguchi iD, Ei Itobayashi iD, Takashi Nishimura iD, Kunihiko Tsuji iD, Toru Ishikawa iD und 46 weitere

Liver International · 2026

DOI: 10.1111/liv.70570 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Tomomitsu Matono und 57 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Harima Himeji General Medical Center, Himeji, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Monocytes, Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims This multicenter retrospective study in Japan aimed to investigate the prognostic significance of lymphocyte‐to‐monocyte ratio (LMR) in patients with unresectable hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre).

Methods

A total of 377 patients with HCC and treated with Dur/Tre across 30 institutions in Japan were included in this multicenter study. Time‐dependent receiver operating characteristic (ROC) analysis was performed to determine the optimal LMR cut‐off value. Hazard ratio (HR) spline curve analysis was used to identify the optimal LMR range for predicting progression‐free survival (PFS) and overall survival (OS).

Results

Time‐dependent ROC analysis identified an optimal LMR cut‐off value of 2.52 for predicting median OS. Multivariate analysis demonstrated that an LMR of ≥ 2.52 was independently associated with superior PFS (HR: 0.777) and OS (HR: 0.657). The median PFS was 2.6 months in patients with an LMR of < 2.52, compared with 3.5 months in those with an LMR of ≥ 2.52 ( p = 0.022). The median OS was 12.8 months in patients with an LMR of < 2.52, compared with 23.4 months in those with an LMR of ≥ 2.52 ( p < 0.001). The disease control rate was significantly higher in the high LMR group ( p = 0.032). The HR spline curve analysis revealed that an LMR range of approximately 1.8–2.6 represents an optimal cut‐off for predicting both PFS and OS.

Conclusions

LMR is a readily accessible prognostic biomarker for both PFS and OS in patients with unresectable HCC treated with Dur/Tre, and may serve as a practical tool for risk stratification in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularMonocytesAntibodies, MonoclonalLymphocytesAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, Monoclonal, HumanizedFemaleRetrospective StudiesMaleMiddle AgedAgedJapanPrognosisROC CurveProgression-Free SurvivalAntineoplastic Agents, ImmunologicalLymphocyte CountAged, 80 and overAdult

Stichwörter der Autor:innen

durvalumabhepatocellular carcinomalymphocyte‐to‐monocyte ratiosurvivaltremelimumab

Substanzen

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonaltremelimumabdurvalumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Gastroenterology, Harima Himeji General Medical Center, Himeji, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.

ORCID-Profile: Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Taeang Arai, Akemi Tsutsui, Shinya Fukunishi, Kazunari Tanaka, Yuki Kanayama, Hidenao Noritake, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

Zitieren

APA

Matono, T., Tada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Nishimura, T., Tsuji, K., Ishikawa, T., Tajiri, K., Tanaka, H., Toyoda, H., Ogawa, C., Hatanaka, T., Kakizaki, S., Kawata, K., …, & RELPEC Group and HCC 48 Group (2026). Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab. Liver International. https://doi.org/10.1111/liv.70570

Vancouver

Matono T, Tada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, et al. Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab. Liver International. 2026. doi:10.1111/liv.70570

BibTeX
@article{Matono2026,
  author = {Matono, Tomomitsu and Tada, Toshifumi and Hiraoka, Atsushi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Nishimura, Takashi and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Tanaka, Hironori and Toyoda, Hidenori and Ogawa, Chikara and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Naganuma, Atsushi and Kosaka, Hisashi and Kuroda, Hidekatsu and Yata, Yutaka and Nishikawa, Hiroki and Imai, Michitaka and Aoki, Tomoko and Ochi, Hironori and Tamai, Hideyuki and Komatsu, Shohei and Matsuura, Takanori and Ueda, Yoshihide and Kim, Soo Ki and Ohama, Hideko and Tada, Fujimasa and Nakamura, Shinichiro and Nakamura, Yoshiko and Yoshida, Osamu and Nouso, Kazuhiro and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Tsutsui, Akemi and Nagano, Takuya and Fukunishi, Shinya and Tanaka, Kazunari and Koshiyama, Yuichi and Kanayama, Yuki and Noritake, Hidenao and Enomoto, Hirayuki and Matsui, Kosuke and Kaibori, Masaki and Okamura, Jumpei and Fukumoto, Takumi and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and RELPEC Group and HCC 48 Group, RELPEC Group and HCC 48 Group},
  title = {Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70570}
}
Kostenlos starten →